A. Abbruzzi

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

Ayca Gucalp, Joseph A. Sparano, James F. Caravelli et al. · Clinical Breast Cancer · 2011 · 159 citations · Full text

Medicine, Oncology, Pharmacology +13

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

Patrick G. Morris, Carol Chen, Richard M. Steingart et al. · Clinical Cancer Research · 2011 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Monica Fornier, Patrick G. Morris, A. Abbruzzi et al. · Annals of Oncology · 2011 · 70 citations · Full text

Medicine, Oncology, Pharmacology +13

Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/<i>neu</i>–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

Chau T. Dang, Nancy U. Lin, Beverly Moy et al. · Journal of Clinical Oncology · 2010 · 43 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

Patrick G. Morris, Neil M. Iyengar, Sujata Patil et al. · Cancer · 2013 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16